GlassScriptPhysician profile
Gregory Alan Prier
NPI 1932257169
$3,350.92
in general payments reported to CMS, 2019-2025
16 companies · $588 in 2025
The $588 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2023: $990 · 2024: $1,575 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,041 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,041.36 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $724.69 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $584.07 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Alkermes, INC. | $529.10 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $285.76 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $262.12 | 2023-2024 | Caplyta |
| Abbvie INC. | $229.25 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $200.28 | 2023-2025 | Ingrezza |
| Indivior INC. | $117.21 | 2023-2024 | Perseris |
| Vanda Pharmaceuticals INC. | $86.45 | 2024 | Fanapt, Hetlioz |
| Lundbeck LLC | $85.77 | 2023-2024 | Rexulti |
| Allergan, INC. | $61.49 | 2019 | |
| Axsome Therapeutics, INC. | $58.69 | 2023-2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $48.33 | 2024 | Cobenfy |
| Corium, LLC | $40.79 | 2023 | Azstarys |
| Eisai INC. | $18.98 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $17.94 | 2024 | Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Prier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.